← Eichor
Study identifier: NCT06783270 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

Condition: Melanoma Metastatic  ·  Sponsor: Inge Marie Svane

PhasePhase 1
Planned participants10
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The purpose of this study is to assess wether it is safe and feasible to treat patients with tumor infiltrating lymphocytes that have been silenced for PD-1, using CRISPR-Cas9.

This description comes directly from the study's public registry record.

Talk to the study team

Joel E Sohlin, MD  ·  +4538689198  ·  joel.emanuel.sohlin@regionh.dk

Inge Marie Svane, MD, phd, prof  ·  +4538682131  ·  inge.marie.svane@regionh.dk

Always discuss trial participation with your own doctor first.

Locations (1)

CCIT-DKHerlev, Capital Region, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06783270